No phaseRecruiting
Assessment of the Immunomodulatory Potential of Spirulina Blue Protein Capsule on Immunomodulation in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunomodulatory Potential and Safety of Spirulina Blue Protein Capsules in Healthy Volunteers
- Sponsor
- University of Phayao (Academic or other)
- Enrollment
- 54 planned
- Conditions
- Healthy Volunteers; Immune System
- Interventions
- Spirulina capsules
- Ages
- adults
- Registry
- NCT07733362, TCTR20260719002
Full record on ClinicalTrials.gov
From the registry
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and immunomodulatory effects of Spirulina Blue Protein capsules in healthy adults. Participants will be randomly assigned to receive placebo, 200 mg/day, or 1,000 mg/day of Spirulina Blue Protein capsules for 12 weeks. The study will assess changes in immune cell populations (CD4+, CD8+, and natural killer cells), circulating cytokine levels, hematological and biochemical parameters, and the occurrence of adverse events. The findings will provide evidence regarding the safety and potential immunomodulatory benefits of Spirulina Blue Protein supplementation in healthy individuals and support the development of evidence-based functional food and nutraceutical products.
Primary outcomes
- Change in Peripheral Blood Immune Cell Subsets
History
Study completion expected
Primary completion expected
Started
Registered